Abstract
One of the greatest challenges in Alzheimer's disease (AD) is the discovery of new non-invasive, sensitive and specific biomarkers, which might be useful in prodromal phases like mild cognitive impairment (MCI) and subjective cognitive decline (SCD). Neurofilament light chain (NfL), a component of neuronal cytoskeleton, is becoming increasingly notable in different neurological diseases including AD, as a valuable marker of neuronal damage. We aimed to assess quantitative differences in plasma NfL levels between SCD, MCI and AD patients investigating the role of NfL in the early stages of AD.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call